Fungus dubbed ‘mummy's curse' could make a powerful cancer drug, new study reveals
Researchers believe that a fungus thought to be found in ancient tombs may provide a valuable new tool in the fight against cancer.
The fungus Aspergillus flavus, sometimes dubbed the 'mummy's curse' for its potential link to the deaths of archaeologists who excavated famous tombs like that of King Tutankhamen in Egypt, shows promise in stopping cancers such as leukemia, according to a new study published Monday in Nature Chemical Biology from a team of scientists led by the University of Pennsylvania.
'Fungi gave us penicillin,' Sherry Gao, associate professor in chemical and biomolecular engineering and bioengineering at Penn, a senior author on the study, said in a statement. 'These results show that many more medicines derived from natural products remain to be found.'
Over the course of their research, the scientists isolated and purified a new class of molecules derived from the fungus, asperigimycins, and tested them against common cancers in breast, liver, and lung cells.
Even with no modification, two of the four asperigimycins in the experiment had 'potent' effects against leukemia cells, according to the university.
Another variation, to which scientists added a fatty lipid molecule, performed as well as the longstanding Food and Drug Administration-approved leukemia drugs cytarabine and daunorubicin, the university added.
Researchers believe these molecules, created inside the fungus's cellular machinery then modified by the study's authors, block some of the mechanisms of cell division, halting the unchecked cell growth that causes cancer.
'Cancer cells divide uncontrollably,' Gao added in the statement. 'These compounds block the formation of microtubules, which are essential for cell division.'
Aspergillus flavus, which is commonly found in soil, can lead to lung infections in humans, especially among those with compromised immune systems, and infects a variety of agricultural crops.
As a result, it is one of the most frequently isolated mold species in agriculture and medicine, according to Popular Science.
The Penn team, which also included researchers from Rice University, the University of Pittsburg, the University of Texas, Washington University of St. Louis, Baylor College of Medicine, and the University of Porto, said its research was unique because it focused on a class of peptides more commonly studied in bacteria, rather than fungus.
The research, which scientists hope to continue in animal models and potential human trials down the road, was funded by the National Institutes of Health, the biomedical research hub from which the Trump administration hopes to cut $18 billion in funding.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
BreakingNews.ie
an hour ago
- BreakingNews.ie
Samantha Womack: ‘Following my instincts saved my life'
Although she felt fit and healthy, actress Samantha Womack had a gut feeling that something was wrong with her. So she had a private ultrasound scan of her breasts which found a 4cm cancerous tumour. Advertisement Three years after the shock discovery, Womack is clear of cancer after having the tumour removed, plus chemotherapy and radiotherapy. View this post on Instagram A post shared by Sam Womack (@samzjanus) But she's urging other women to follow their instincts if they're concerned about their health in any way, and stresses: 'If anything feels wrong, you just have to get as much information as you can and get it checked out, because it literally saved my life 'I wasn't quite 50, and I didn't have a lump – I didn't have any symptoms. I was generally healthy, and for some reason I just had an instinct that maybe something wasn't right. So in the middle of two shows, I went to get an ultrasound, and saw a black shadow there. Immediately, when I saw it was an irregular shape, I thought 'I know what that is'.' Womack, who played Ronnie Mitchell in EastEnders until 2017, was diagnosed with an aggressive grade three invasive ductal carcinoma in her right breast. The cancer had already started to travel to her lymph nodes, and she had five nodes removed. 'The journey then became very much about listening to my instincts and responding to what my body needed, and getting as much information as I could about the cancer,' she explains, 'because what if I hadn't listened to my intuition, my other voice? My diagnosis and treatment would have been very different.' Advertisement (Alamy/PA) Now Womack, 52, who divides her time between the UK and her home in the mountains near Valencia in Spain, is championing a campaign to get women who are undergoing breast cancer tests to ask whether their breast tissue is dense or not. The Keep Abreast of your Breast Density campaign by private cancer care provider GenesisCare explains that although mammograms are an excellent breast cancer screening tool, it's harder to spot tumours in mammograms of dense breast tissue, which is a measurement of how much fibroglandular tissue there is in a woman's breast versus fatty tissue. GenesisCare says dense breast tissue is found in around half of women aged over 40, and women with extremely dense breasts are six times more likely to get breast cancer than those with fatty breasts. However, women in the UK are not currently informed about their breast density following a mammogram, and no further additional imaging is offered for women with dense breasts. Womack says she still doesn't know if she has dense breasts herself, pointing out: 'During the whole process, I hadn't understood about dense breasts – no-one had mentioned the term to me. But then when I understood, I learned that the denser your breasts, an all-clear with a mammogram doesn't necessarily mean you're clear. If you've got fatty breasts, tumours are easy to see, but as they become more fibrous, it's more difficult.' Advertisement Womack is urging women to ask doctors whether they have dense breasts or not, and if they have, then decide whether they want any further tests after a mammogram. 'We still have this mentality of doctors know best and you shouldn't really push the health service because they're doing all they can,' she says. 'A lot of the time that's right. But if you feel like there's anything wrong, and you're not quite 50, or you're over 50 and you've had a mammogram and you've been given the all-clear, but something still doesn't feel right, the information about whether you have dense breasts can massively change your treatment. 'I just realised how ill-informed we are, and how nervous sometimes we are to ask questions. It's about taking control of your own body. If anything feels wrong, if you've got a lump that's persistent and won't go away, if you've had a mammogram and it doesn't feel right, or something is telling you that you should go back, you should listen to that. 'And you absolutely should ask what density your breasts are, because it really makes a difference in terms of finding tumours.' Advertisement Womack now has check-ups every six months, and says she's trying to lead a healthier lifestyle, enjoying walking her six rescue dogs in the mountains around Valencia, where she lives part-time with her partner, actor Oliver Farnworth who plays John Sugden in Emmerdale. View this post on Instagram A post shared by Sam Womack (@samzjanus) 'I've just chosen to be around nature – it's a calmer lifestyle. It's quieter,' she says happily. 'That's not just because of the cancer – I just enjoy it. I walk the dogs every day, and I try to make good choices about my body. I'm just listening to my body a lot more, I think, rather than being panicked about what I eat and how much I sleep. You can be neurotic about those kind of things. I'm sensible. 'But the main thing is if anything's wrong, I follow my instinct and I get it checked out. And I really encourage all women to do the same and not be afraid to ask questions.' But what do independent experts have to say about dense breasts and cancer screening? Advertisement View this post on Instagram A post shared by Breast Cancer Now (@breastcancernow) Sally Kum, associate director of nursing and health information at the Breast Cancer Now charity, confirms: 'Having dense breasts both increases the risk of breast cancer and makes it harder to identify potential cancers on a routine mammogram.'
Times
3 hours ago
- Times
Toxic fungus linked to ‘pharoah's curse' could help fight cancer
A toxic fungus linked to the mysterious deaths of archaeologists who opened ancient tombs including that of Tutankhamun could be used to make a drug to tackle blood cancer. The theory of a 'pharoah's curse' grew after a series of untimely deaths struck down several members of the team who excavated Tutankhamun's tomb in the 1920s. In the 1970s, 12 scientists entered a tomb in Poland that belonged to Casimir IV, who was Grand Duke of Lithuania from 1440 and King of Poland from 1447. Within weeks, ten of them were dead. It emerged that the tomb contained Aspergillus flavus, a toxic crop fungus with yellow spores that can lead to lung infections, particularly in those with weakened immune systems. However, researchers have found that the fungus could contain one of a class of peptides known as RiPPs, pronounced 'rips', that can be modified to attack cancer. 'Purifying these chemicals is difficult,' said Dr Qiuyue Nie from the University of Pennslyvania, an author of the paper published in the journal Nature Chemical Biology. 'The synthesis of these compounds is complicated, but that's also what gives them this remarkable bioactivity.' A number of these RiPPs had been found in bacteria but few had been found in fungi. They found that a particular protein within the Aspergillus flavus fungus was a promising candidate. Howard Carter, the British archaeologist, led the team that explored Tutankhamun's tomb. His benefactor, Lord Carnarvon, died six weeks after they entered the tomb TIMES PHOTOGRAPHER BILL WARHURST, COLOURISED BY UNSEEN HISTORIES/JORDAN J LLOYD AND JOSHUA BARRETT 'Even with no modification, when mixed with human cancer cells, the asperigimycins [protein] demonstrated medical potential. Two of the four variants had potent effects against leukaemia cells,' the research showed. After adding a fatty molecule to another variant, they found that it worked as well as 'two drugs that have been used for decades to treat leukaemia'. It appears that the protein may disrupt the division of the cancer cells. 'Fungi gave us penicillin,' said Sherry Gao, a professor at the university. 'These results show that many more medicines derived from natural products remain to be found.' It could be many years before a drug can be produced for testing and use in humans, however. 'The next step is to test asperigimycins in animal models, with the hope of one day moving to human clinical trials,' the researchers said. 'Nature has given us this incredible pharmacy,' Gao said. 'It's up to us to uncover its secrets. As engineers, we're excited to keep exploring, learning from nature and using that knowledge to design better solutions.'
Daily Mirror
4 hours ago
- Daily Mirror
'Curse' which killed explorers entering Egyptian tombs could fight cancer
When people died after entering the ancient pyramids for the first time it was blamed on a Pharaoh's Curse or Mummy's Revenge The "Pharaoh's Curse" which killed archaeologists, scientists and explorers who broke into the tombs of ancient kings in Egypt has been transformed into an anti-cancer drug. After archaeologists opened King Tutankhamun's tomb in the 1920s, a series of untimely deaths among the excavation team fuelled rumours of a "pharaoh's curse". A dozen scientists entered the tomb of Casimir IV in Poland In the 1970s but, within weeks, 10 of them died. Decades later, doctors theorised that fungal spores, dormant for millennia, could have played a role. Scientists isolated a new class of molecules from Aspergillus flavus, a toxic crop fungus linked to infamous deaths following the excavations of ancient tombs. Later investigations revealed the tomb contained A. flavus, whose toxins can lead to lung infections, especially in people with compromised immune systems. Now, that same fungus is the unlikely source of a promising new cancer therapy. American scientists modified the chemicals they isolated from A. flavus and tested them against leukaemia cells. Their findings, published in the journal Nature Chemical Biology, showed a "promising" cancer-killing compound that rivals already-approved drugs - and opens new frontiers for fungal medicines. Study senior author Professor Sherry Gao, of the University of Pennsylvania, said: 'Fungi gave us penicillin. 'These results show that many more medicines derived from natural products remain to be found.' She explained that the therapy in question is a class of ribosomally synthesised and post-translationally modified peptides, or RiPPs. The name refers to how the compound is produced - by the ribosome, a tiny cellular structure that makes proteins - and the fact that it is modified later to enhance its cancer-killing properties. Study first author Dr Qiuyue Nie said: 'Purifying these chemicals is difficult." She says that while thousands of RiPPs have been identified in bacteria, only a handful have been found in fungi. Dr Nie said that is because researchers previously misidentified fungal RiPPs as non-ribosomal peptides and had little understanding of how fungi created the molecules. She added: 'The synthesis of these compounds is complicated. But that's also what gives them this remarkable bioactivity.' To find more fungal RiPPs, the research team first scanned a dozen strains of Aspergillus, which previous research suggested might contain more of the chemicals. By comparing chemicals produced by these strains with known RiPP building blocks, the researchers identified A. flavus as a "promising" candidate for further study. Genetic analysis pointed to a particular protein in A. flavus as a source of fungal RiPPs. When the researchers turned the genes that create that protein off, the chemical markers indicating the presence of RiPPs also disappeared. They said the new approach - combining metabolic and genetic information - not only pinpointed the source of fungal RiPPs in A. flavus, but could also be used to find more fungal RiPPs in the future. Further experiments suggested that asperigimycins likely disrupt the process of cell division. Prof Gao said: 'Cancer cells divide uncontrollably. These compounds block the formation of microtubules, which are essential for cell division.' She says the compounds had little to no effect on breast, liver or lung cancer cells - or a range of bacteria and fungi - suggesting that asperigimycins' disruptive effects are specific to certain types of cells, a critical feature for any future medication. As well as showing the medical potential of asperigimycins, the research team also identified similar clusters of genes in other fungi, suggesting that more fungal RiPPS remain to be discovered. Dr Nie said: 'Even though only a few have been found, almost all of them have strong bioactivity. This is an unexplored region with tremendous potential.' The researchers say the next step is to test asperigimycins in animal models, with the hope of one day moving to human clinical trials. Prof Gao added: 'Nature has given us this incredible pharmacy. It's up to us to uncover its secrets. As engineers, we're excited to keep exploring, learning from nature and using that knowledge to design better solutions.'
